Eltrombopag
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Immune Thrombocytopenic Purpura (ITP)
Conditions
Immune Thrombocytopenic Purpura (ITP)
Trial Timeline
Jul 1, 2016 → Sep 1, 2017
NCT ID
NCT02877212About Eltrombopag
Eltrombopag is a phase 3 stage product being developed by Novartis for Immune Thrombocytopenic Purpura (ITP). The current trial status is unknown. This product is registered under clinical trial identifier NCT02877212. Target conditions include Immune Thrombocytopenic Purpura (ITP).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04837703 | Pre-clinical | Active |
| NCT05286164 | Phase 2 | UNKNOWN |
| NCT03988608 | Phase 2 | Completed |
| NCT03718533 | Phase 2 | Terminated |
| NCT03664518 | Phase 2 | Completed |
| NCT03524612 | Phase 2 | Completed |
| NCT02877212 | Phase 3 | UNKNOWN |
| NCT02323178 | Phase 1/2 | Completed |
| NCT01703169 | Phase 2 | Completed |
| NCT01715779 | Pre-clinical | Completed |
| NCT01416311 | Pre-clinical | Completed |
Competing Products
20 competing products in Immune Thrombocytopenic Purpura (ITP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Placebo + Lusutrombopag | Shionogi | Phase 2 | 52 |
| Lusutrombopag | Shionogi | Phase 2 | 52 |
| Romiplostim | Kyowa Kirin | Phase 1/2 | 41 |
| AMG 531 | Kyowa Kirin | Phase 2/3 | 65 |
| Romiplostim + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Romiplostim (AMG-531) | Kyowa Kirin | Phase 2 | 52 |
| Romiplostim and danazol | Kyowa Kirin | Phase 2 | 52 |
| Hetrombopag Olamine | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Herombopag | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zostavax® | Merck | Pre-clinical | 23 |
| Raltegravir + Atazanavir | Merck | Pre-clinical | 23 |
| Zostavax | Merck | Pre-clinical | 23 |
| MK-8723 + Matching Placebo | Merck | Phase 1 | 33 |